C. L. Beach

发表

Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.

G. Mufti, P. Fenaux, K. Ozawa, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Feasibility of using recipients of health promotional newsletters for post-marketing surveillance.

D. Ford, M. Klag, L. Mead, 2000, Journal of clinical epidemiology.

Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial

G. Garcia-Manero, P. Fenaux, N. Vey, 2018, Leukemia & lymphoma.

Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher‐risk myelodysplastic syndromes

G. Mufti, B. Skikne, J. Bennett, 2014, British journal of haematology.

The Effect of Lenalidomide on Health‐Related Quality of Life in Patients With Lower‐Risk Non‐del(5q) Myelodysplastic Syndromes: Results From the MDS‐005 Study

P. Fenaux, A. Giagounidis, U. Platzbecker, 2017, Clinical lymphoma, myeloma & leukemia.

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

A. Stamatoullas, B. Quesnel, P. Fenaux, 2011, Blood.

Antianginal Response to Once‐Daily Diltiazem CD in Patients Receiving Concomitant β‐Blockers, Long‐Acting Nitrates, or Both

S. Glasser, G. Heller, C. L. Beach, 1997, Pharmacotherapy.

Control of heart rate during transition from intravenous to oral diltiazem in atrial fibrillation or flutter.

B. Stambler, W. Strauss, D. Roy, 1996, The American journal of cardiology.

Long‐Acting Diltiazem CD Is Safe and Effective in a Hypertensive Mexican‐American Population

A. Lewin, C. L. Beach, T. Baker, 1997, Pharmacotherapy.

Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients

T. Haferlach, K. Mavrommatis, P. Fenaux, 2020, Leukemia.

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

J. Bennett, P. Fenaux, E. Hellström-Lindberg, 2013, Haematologica.

A Phase I Study in Patients with Solid or Hematologic Malignancies of the Dose Proportionality of Subcutaneous Azacitidine and Its Pharmacokinetics in Patients with Severe Renal Impairment

A. Mita, N. Gabrail, S. Goel, 2014, Pharmacotherapy.

Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine *

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2010, European journal of haematology.

Prolonged survival with improved tolerability in higher‐risk myelodysplastic syndromes: azacitidine compared with low dose ara‐C

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2010, British journal of haematology.

Time-dependent decision analysis: Stable disease in azacitidine (AZA)-treated patients (pts) with higher-risk MDS.

J. Bennett, P. Fenaux, E. Hellström-Lindberg, 2010 .

Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission

G. Mufti, J. Bennett, P. Fenaux, 2008 .

Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen.

A. Hagemeijer, G. Mufti, B. Skikne, 2009 .

Treatment of high-risk MDS patients (pts) with -7/del(7q) with azacitidine (AZA) versus conventional care regimens (CCR): Effects on overall survival (OS)

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2008 .

PROLONGED SURVIVAL IN HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) PATIENTS (PTS) WITH-7/DEL(7Q) TREATED WITH AZACITIDINE (AZA)

G. Mufti, B. Quesnel, G. Garcia-Manero, 2008 .

A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS

M. Cazzola, H. Deeg, P. Greenberg, 2011 .

116 THE EFFECT OF LENALIDOMIDE ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH MDS: RESULTS FROM THE MDS-005 TRIAL

B. Skikne, P. Fenaux, X. Hu, 2015 .

115 MDS-005 STUDY: EFFECT OF BASELINE ENDOGENOUS EPO ON RBC TRANSFUSION INDEPENDENCE (RBC-TI) IN LENALIDOMIDE-TREATED PATIENTS WITH LOW/INTERMEDIATE-1-RISK MDS WITHOUT DEL(5Q)

B. Skikne, P. Fenaux, A. Giagounidis, 2015 .

Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (≥75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial

L. Silverman, G. Mufti, P. Fenaux, 2008 .

Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomize

G. Mufti, P. Fenaux, K. Ozawa, 2014 .

Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer

B. Skikne, M. Abdelrahim, M. Milhem, 2020, Cancer Chemotherapy and Pharmacology.

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

H. Dombret, G. Mufti, P. Fenaux, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes

C. Pashos, P. Fenaux, Z. Khan, 2012, Journal of medical economics.

Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.

M. Cazzola, H. Deeg, P. Greenberg, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bioavailability of Azacitidine Subcutaneous Versus Intravenous in Patients With the Myelodysplastic Syndromes

G. Marcucci, M. Eller, L. Silverman, 2005, Journal of clinical pharmacology.

Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.

B. Esterni, B. Quesnel, P. Fenaux, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2010, Critical reviews in oncology/hematology.

Cardiac Conduction Abnormalities and Atrial Arrhythmias Associated with Salicylate Toxicity

C. L. Beach, Martin A. Alpert, Vaskar Mukerji, 1986, Pharmacotherapy.

Outcome of Patients (pts) Treated for Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (s AML) After Azacitidine (AZA) Failure

B. Esterni, P. Fenaux, S. Thépot, 2010 .

Dose-response evaluation of once-daily therapy with a new formulation of diltiazem for stable angina pectoris. Diltiazem CD Study Group.

S. Glasser, U. Thadani, N. Bittar, 1994, The American journal of cardiology.

Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis

B. Smith, H. Henk, C. L. Beach, 2014, Experimental Hematology & Oncology.

Efficacy of Betaxolol in the Treatment of Stable Exertional Angina Pectoris: A Dose-Ranging Study

G. Flaker, M. Alpert, V. Mukerji, 1990, Angiology.

EFFECT OF AZACITIDINE (AZA) vs LOW-DOSE ARA-C (LDAC) ON OVERALL SURVIVAL (OS), HEMATOLOGIC RESPONSE, TRANSFUSION INDEPENDENCE, AND SAFETY IN PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)

H. Dombret, G. Mufti, P. Fenaux, 2008 .

Correction: Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis

B. Smith, H. Henk, C. L. Beach, 2014, Experimental Hematology & Oncology.

A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes

C. Pashos, P. Fenaux, Z. Khan, 2012, Journal of medical economics.

Achievement of Red Blood Cell (RBC) Transfusion Independence with Azacitidine (AZA) Leads to Improved Survival In Patients with Higher-Risk Myelodysplasias Regardless of Baseline Transfusion Needs

P. Fenaux, C. Finelli, A. Giagounidis, 2010 .